Summary

CAR T Cell Therapy Market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, and Others), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World), Key Players and Sales Forecast
Report Link: https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html
The CAR T Cell Therapy Market is expected to reach 4.6 billion in 2024 anticipated to grow at a CAGR of 20% during the forecast period 2024-2035.

Cancer remains a prominent global cause of mortality, as estimated by the World Health Organization (WHO) reporting 10 million cancer-related deaths in 2020 alone. Projections indicate a significant escalation in the global cancer burden by 2040, with an estimated 27.5 million new cases anticipated. This surge places substantial physical, emotional, and financial strain on affected individuals, families, communities, and national health systems. Conventional treatment modalities, including chemotherapy, radiation therapy, and surgery, are currently employed for various cancers. Despite the array of available treatments aimed at controlling disease progression and arresting the spread of malignant cells, achieving lasting remission remains a considerable challenge. In response to the limitations of conventional treatments, active initiatives are underway to develop more targeted anti-cancer therapies. Among these, CAR T cell therapies have emerged as promising options due to their ability to eliminate tumor cells with minimal treatment-related side effects. Immunotherapies utilize the body's immune system or its components to combat cancer. Various classes of immunotherapies, such as therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors, and certain whole cell-based therapies, have emerged as alternatives for cancer management and treatment.
CAR-T cell therapy, a recent addition to anticancer interventions, has demonstrated significant success alongside targeted antibody-based therapeutics like monoclonal and conjugated antibodies. This highly specific form of cell therapy, leveraging the versatile effector machinery of the human immune system, has brought about a revolution in cancer treatment on a global scale. Ongoing research in this field continues to unveil novel molecular targets, thereby enhancing the research pipelines of companies operating in this domain. With an increasing number of CAR T cell therapies in development and entering the market, the CAR T cell therapy market is poised to become one of the most valuable segments within the biopharmaceutical industry.


Research Coverage:
Comprehensive assessment of current market landscape of CAR-T cell therapies with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, this chapter also includes developer landscape analysis based on the relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
Detailed assessment of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to haematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
Detailed analysis of completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
An informative analysis highlighting the key opinion leaders (KOLs) featuring an assessment of the principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Detailed company profiles of leading players in this domain. Each company profile includes a company overview and brief description of the product portfolio, technology portfolio, recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
An insightful assessment of different types of partnership that have been inked between several stakeholders in this domain, on various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
Comprehensive insights on the analysis of the funding and investment analysis that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
An in-depth assessment of the patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
A detailed assessment of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
Comprehensive analysis of various factors that can influence the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Detailed predictions of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
Detailed projections of the current and future CAR T-cell therapy market across types of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
Detailed projections of the current and future CAR T cell therapy market across leading players.
Detailed predictions of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), Ciltacabtagene Autoleucel (CARVYKTI™) and others.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Alaunos Therapeutics
Autolus
Abelzeta Pharma
Bluebird Bio
Bristol Myers Squibb
Carsgen Therapeutics
Cellectis
Gilead Sciences
Innovative Cellular Therapeutics
Kuur Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
5.2.1. Historical Evolution
5.2.2. Key Considerations for Developing T-cell Immunotherapies
5.2.3. Strategies Employed for the Redirection of T-cells
5.2.4. Manufacturing of Engineered T-cells

5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
5.3.1. Development History
5.3.2. Structure of CAR
5.3.2.1. Ectodomain
5.3.2.2. Transmembrane (TM) Domain
5.3.2.3. Endodomain

5.3.3. Development of CAR-T Cells
5.3.4. Universal CAR-T Cells
5.3.5. Route of Administration

5.3.6. Challenges Associated with CAR-T Cell Therapies
5.3.6.1. Competitive Risks
5.3.6.2. Clinical Risks
5.3.6.3. Regulatory Risks
5.3.6.4. Commercial Risks

5.4. Concluding Remarks

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Type of Therapy
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Phase of Development and Therapeutic Area
6.2.6. Analysis by Key Target Indication
6.2.7. Analysis by Key Target Antigen
6.2.8. Analysis by Source of T-cells
6.2.9. Analysis by Phase of Development and Source of T-cells
6.2.10. Analysis by Route of Administration
6.2.11. Analysis by Dosing Frequency
6.2.12. Analysis by Target Patient Population
6.2.13. Most Active Industry Players: Analysis by Number of Therapies
6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies

6.3. CAR-T Cell Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors

7.3. CAR-T Therapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Type of Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis of Enrolled Patient Population by Trial Phase
8.3.7. Analysis by Target Patient Population
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Area
8.3.13. Analysis by Geography

9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Geographical Location of KOLs
9.4.4. KOL Activeness versus KOL Strength
9.4.5. Most Prominent KOLs: Analysis by RA score
9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Alaunos Therapeutics
10.3. Autolus
10.4. Bluebird Bio
10.5. Bristol Myers Squibb
10.6. Carsgen Therapeutics
10.7. Cellectis
10.8. AbelZeta Pharma
10.9. Gilead Sciences
10.10. Innovative Cellular Therapeutics
10.11. Kuur Therapeutics
10.12. Noile-Immune Biotech
10.13. Novartis
10.14. Shanghai GeneChem
10.15. Sinobioway Cell Therapy
10.16. Takara Bio
10.17. Wellington Zhaotai Therapies

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapies: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

11.3.8. Analysis by Geography
11.3.8.1. Intercontinental and Intracontinental Agreements
11.3.8.2. International and Local Agreements

12. FUNDING AND INVESTMENTS ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapies: Funding and Investment Analysis
12.3.1. Analysis by Year of Funding
12.3.2. Analysis of Amount Invested by Year
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of Investor
12.3.5. Most Active Players: Analysis by Amount Invested
12.3.5. Most Active Players: Analysis by Number of Funding Instances
12.3.7. Most Active Players: Analysis by Amount Invested
12.3.8. Most Active Investors: Analysis by Amount Invested
12.3.9. Most Active Investors: Analysis by Number of Funding Instances

12.3.10. Analysis by Geography
12.3.10.1. Analysis of Number of Instances by Geography
12.3.10.2. Analysis of Amount Invested by Geography

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. CAR-T Cell Therapies: Patent Analysis
13.3.1. Analysis by Patent Publication Year
13.3.2. Analysis by Patent Application Year
13.3.3. Analysis by Patent Jurisdiction
13.3.4. Analysis by Type of Player
13.3.5. Analysis by CPC Symbols
13.3.6. Leading Industry Players: Analysis by Number of Patents
13.3.7. Leading Non-Industry Players: Analysis by Number of Patents
13.3.8. Leading Individual Assignees: Analysis by Number of Patents

13.3.9. Patent Benchmarking Analysis
13.3.9.1. Analysis by Patent Characteristics
13.3.9.2. Patent Valuation
13.3.9.3. Leading Patents by Number of Citations

14. CASE STUDY: CELL THERAPY MANUFACTURING
14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing
14.3. Cell Therapy Manufacturing Models
14.3.1. Centralized Manufacturing Model
14.3.2. Decentralized Manufacturing Model

14.4. Scalability of Cell Therapy Manufacturing Processes
14.4.1. Scale-Up
14.4.2. Scale-Out

14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies

14.7. Key Considerations for Cell Therapy Manufacturing
14.7.1. Characterization
14.7.2. Cost of Goods

14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives

15. COST PRICE ANALYSIS
15.1 Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies
15.3. Pricing Models for T-cell Immunotherapies
15.3.1. Based on Associated Costs
15.3.2. Based on Availability of Competing Products
15.3.3. Based on Patient Population
15.3.4. Based on Opinions of Industry Experts

15.4. Reimbursement related Considerations for T-cell Immunotherapies
15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL CAR-T CELL THERAPY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035), till 2035
17.4. Scenario Analysis
17.4.1. Conservative Scenario
17.4.2. Optimistic Scenario

17.5. CAR-T Cell Therapy Market: Drug-wise Sales Forecast, Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.6. Key Market Segmentations

18. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024, 2030 and 2035
18.3.1. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.2. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Historical Trends and Future Estimates, Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.3. CAR-T Cell Therapy Market for Multiple Myeloma: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.4. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.5. CAR-T Cell Therapy Market for Other Indications: Historical Trends (2018-2023) and Future Estimates (2024-2035)

18.6. Data Triangulation and Validation

19. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024, 2030 and 2035
19.3.1. CAR-T Cell Therapy Market for CD19: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.2. CAR-T Cell Therapy Market for BCMA: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.3. CAR-T Cell Therapy Market for Other Target Antigens: Historical Trends (2018-2023) and Future Estimates (2024-2035)

19.4. Data Triangulation and Validation

20. CAR-T CELL THERAPY MARKET, BY KEY PLAYERS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Key Players
20.4. Data Triangulation and Validation

21. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
21.3.1. CAR-T Cell Therapy Market in North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.2. CAR-T Cell Therapy Market for Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.4. CAR-T Cell Therapy Market for Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)

21.4. Data Triangulation and Validation

22. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS

23. PROMOTIONAL ANALYSIS
23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads

23.5. Kymriah: Promotional Analysis
23.5.1. Drug Overview
23.5.2. Product Website Analysis
23.5.2.1. Message for Healthcare Professionals
23.5.2.2. Message for Patients
23.5.2.3. Informative Downloads

23.5.3. Patient Support Services

23.6. Yescarta: Promotional Analysis
23.6.1. Drug Overview
23.6.2. Product Website Analysis
23.6.2.1. Message for Healthcare Professionals
23.6.2.2. Message for Patients
23.6.2.3. Informative Downloads

23.6.3. Patient Support Services

23.7. Tecartus: Promotional Analysis
23.7.1. Drug Overview
23.7.2. Product Website Analysis
23.7.2.1. Message for Healthcare Professionals
23.7.2.2. Message for Patients
23.7.2.3. Informative Downloads

23.7.3. Patient Support Services

23.8. Breyanzi: Promotional Analysis
23.8.1. Drug Overview
23.8.2. Product Website Analysis
23.8.2.1. Message for Healthcare Professionals
23.8.2.2. Message for Patients
23.8.2.3. Informative Downloads

23.8.3. Patient Support Services

23.9. Abecma: Promotional Analysis
23.9.1. Drug Overview
23.9.2. Product Website Analysis
23.9.2.1. Message for Healthcare Professionals
23.9.2.2. Message for Patients
23.9.2.3. Informative Downloads

23.9.3. Patient Support Services

23.10. Carvykti: Promotional Analysis
23.10.1. Drug Overview
23.10.2. Product Website Analysis
23.10.2.1. Message for Healthcare Professionals
23.10.2.2. Message for Patients
23.10.2.3. Informative Downloads

23.10.3. Patient Support Services

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Glycostem Therapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript

24.3. Gracell Biotechnologies
24.3.1. Company Snapshot
24.3.2. Interview Transcript

24.4. TxCell
24.4.1. Company Snapshot
24.4.2 Interview Transcript

24.5. Kite Pharma
24.5.1. Company Snapshot
24.5.2. Interview Transcript

24.6. Celyad
24.6.1. Company Snapshot
24.6.2. Interview Transcript

24.7. Waisman Biomanufacturing
24.7.1. Company Snapshot
24.7.2. Interview Transcript

24.8. Theravectys
24.8.1. Company Snapshot
24.8.2. Interview Transcript

24.9. Changhai Hospital
24.9.1. Company Snapshot
24.9.2. Interview Transcript

24.10. Changhai Hospital
24.10.1. Company Snapshot
24.10.2. Interview Transcript

25. CONCLUDING REMARKS

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Strategies Employed for the Redirection of T-Cells
Figure 5.2 T-Cell Manufacturing: General Procedure
Figure 5.3 Development History of CAR-T cells
Figure 5.4 Structure of Chimeric Antigen Receptor
Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 5.6 CAR T-Cell Therapies: Development Process
Figure 5.7 Challenges Associated with CAR T-Cell Therapies
Figure 6.1 CAR T Cell Therapy: Distribution by Phase of Development
Figure 6.2 CAR T Cell Therapy: Distribution by Therapeutic Area
Figure 6.3 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Figure 6.4 CAR T Cell Therapy: Distribution by Key Target Indication
Figure 6.5 CAR T Cell Therapy: Distribution by Key Target Antigen
Figure 6.6 CAR T Cell Therapy: Distribution by Source of T- Cells
Figure 6.7 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cells
Figure 6.8 CAR T Cell Therapy: Distribution by Route of Administration
Figure 6.9 CAR T Cell Therapy: Distribution by Dosing Frequency
Figure 6.10 CAR T Cell Therapy: Distribution by Target Patient Segment
Figure 6.11 CAR T Cell Therapy: Distribution by Type of Therapy
Figure 6.12 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 6.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 6.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 6.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 6.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters
Figure 6.17 CAR T Cell Therapy: Distribution by Company Size and Location of Headquarters
Figure 7.1 CAR T Cell Therapy: Popular Targets in Hematological Malignancies
Figure 7.2 CAR T Cell Therapy: Popular
Figure 7.3 CAR-Construction: Distribution by Generation of CAR
Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 . Clinical Trial Analysis: Scope and Methodology
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 8.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 8.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Players: Distribution by Number of Registered Trials
Figure 8.13 Clinical Trial Analysis: Key Focus Areas
Figure 8.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 9.1 KOL Analysis: Distribution by Type of Organization
Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 KOL Analysis: Distribution by Qualification
Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 Most Prominent KOLs: Distribution by RA Score
Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and IntercontinentalAgreements
Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, Pre 2019–2024
Figure12.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2019-2023 (USD Million)
Figure12.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USDMillion)
Figure12.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 12.6 Most Active Players: Distribution by Number of Instances
Figure 12.7 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 12.8 Most Active Investors: Distribution by Number of Instances
Figure 12.9 Most Active Investors: Distribution by Amount Invested
Figure 12.10 Funding and Investment Analysis: Distribution of Number of Instances by Geography
Figure 12.11 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Pre-2018-2024
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Figure 13.4 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.5 Patent Analysis: Distribution by Top CPC Sections
Figure 13.6 Patent Analysis: Cumulative Distribution by Type of Applicant
Figure 13.7 Leading Industry Players: Distribution by Number of Patents
Figure 13.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.10 Top CPC Codes: Benchmarking by Leading Industry Players
Figure 13.11 Leading Industry Players: Benchmarking by Patent Characteristics(CPCCodes)
Figure 13.12 Patent Analysis: Distribution by Patent Age
Figure 13.13 Patent Analysis: Valuation Analysis
Figure 14.1 Steps for Manufacturing Cell Therapies
Figure 14.2 Centralized Manufacturing: Process Model
Figure 14.3 Decentralized Manufacturing: Process Model
Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 14.5 Cell Therapy: Challenges and Drivers
Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk AssessmentConsiderations
Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 16.1. CAR-T Cell Therapies: Market Drivers
Figure 16.2. CAR-T Cell Therapies: Market Restraints
Figure 16.3. CAR-T Cell Therapies: Market Opportunities
Figure 16.4. CAR-T Cell Therapies: Market Challenges
Figure 17.1. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 17.2. Global CAR-T Cell Therapy Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 17.3. Global CAR-T Cell Therapy Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 18.1. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024, 2030 and 2035
Figure 18.2. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.3. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Historical Trends and Future Estimates, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.4. CAR-T Cell Therapy Market for Multiple Myeloma: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.5. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.6. CAR-T Cell Therapy Market for Other Indications: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.1. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024, 2030 and 2035
Figure 19.2. CAR-T Cell Therapy Market for CD19: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.3. CAR-T Cell Therapy Market for BCMA: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.4. CAR-T Cell Therapy Market for Other Target Antigens: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.1. CAR-T Cell Therapy Market: Distribution by Key Player, 2024, 2030 and 2035
Figure 21.1. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
Figure 21.2. CAR-T Cell Therapy Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.3 CAR-T Cell Therapy Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.4 CAR-T Cell Therapy Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.5. CAR-T Cell Therapy Market in Latin America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.6 CAR-T Cell Therapy Market in Middle East and North Africa, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.7 CAR-T Cell Therapy Market in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T) : Sales Forecast, till 2035 (USD Million)
Figure 22.2 CAR-T Cell Therapy Market for Yescarta (axicabtagene ciloleucel) : Sales Forecast, till 2035 (USD Million)
Figure 22.3 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel) : Sales Forecast, till 2035 (USD Million)
Figure 22.4 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121) : Sales Forecast, till 2035 (USD Million)
Figure 22.5 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel) : Sales Forecast, till 2035 (USD Million)
Figure 22.6 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017) : Sales Forecast, till 2035 (USD Million)
Figure 22.7 CAR-T Cell Therapy Market for Carteyva (Relmacabtagene autoleucel / JWCAR029) : Sales Forecast, till 2035 (USD Million)
Figure 22.8 CAR-T Cell Therapy Market for CAR-BCMA T cells : Sales Forecast, till 2035 (USD Million)
Figure 22.9 CAR-T Cell Therapy Market for CAR-T-CD19 Cells : Sales Forecast, till 2035 (USD Million)
Figure 22.10 CAR-T Cell Therapy Market for Descartes-08 : Sales Forecast, till 2035 (USD Million)
Figure 22.11 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1) : Sales Forecast, till 2035 (USD Million)
Figure 22.12 CAR-T Cell Therapy Market for Inaticabtagene Autoleucel (CNCT19 / HY001) : Sales Forecast, till 2035 (USD Million)
Figure 22.13 CAR-T Cell Therapy Market for CAR-T ddBCMA : Sales Forecast, till 2035 (USD Million)
Figure 22.14 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501 : Sales Forecast, till 2035 (USD Million)
Figure 22.15 CAR-T Cell Therapy Market for ALLO-605 : Sales Forecast, till 2035 (USD Million)
Figure 22.16 CAR-T Cell Therapy Market for Descartes-25 : Sales Forecast, till 2035 (USD Million)
Figure 22.17 CAR-T Cell Therapy Market for AUTO1 : Sales Forecast, till 2035 (USD Million)
Figure 22.18 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T) : Sales Forecast, till 2035 (USD Million)
Figure 22.19 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T) : Sales Forecast, till 2035 (USD Million)
Figure 22.20 CAR-T Cell Therapy Market for CD19-CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.21 CAR-T Cell Therapy Market for Humanized CD19-CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.22 CAR-T Cell Therapy Market for IM19 CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.23 CAR-T Cell Therapy Market for CCT301 CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.24 CAR-T Cell Therapy Market for CARCIK-CD19 : Sales Forecast, till 2035 (USD Million)
Figure 22.25 CAR-T Cell Therapy Market for CD123 CAR-T cells : Sales Forecast, till 2035 (USD Million)
Figure 22.26 CAR-T Cell Therapy Market for BCMA CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.27 CAR-T Cell Therapy Market for CD19/CD22-CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.28 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19) : Sales Forecast, till 2035 (USD Million)
Figure 22.29 CAR-T Cell Therapy Market for CD19/CD20-CART : Sales Forecast, till 2035 (USD Million)
Figure 22.30 CAR-T Cell Therapy Market for CD7 CAR-T : Sales Forecast, till 2035 (USD Million)
Figure 22.31 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T / TAA05 : Sales Forecast, till 2035 (USD Million)
Figure 22.32 CAR-T Cell Therapy Market for CT053 : Sales Forecast, till 2035 (USD Million)
Figure 22.33 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells : Sales Forecast, till 2035 (USD Million)
Figure 22.34 CAR-T Cell Therapy Market for WU CART 007 : Sales Forecast, till 2035 (USD Million)
Figure 22.35 CAR-T Cell Therapy Market for Equecabtagene Autoleucel (CT103A) : Sales Forecast, till 2035 (USD Million)
Figure 22.36 CAR-T Cell Therapy Market for TX200-TR101 : Sales Forecast, till 2035 (USD Million)
Figure 22.37 CAR-T Cell Therapy Market for CTX110 : Sales Forecast, till 2035 (USD Million)
Figure 22.38 CAR-T Cell Therapy Market for ALETA-001 : Sales Forecast, till 2035 (USD Million)
Figure 22.39 CAR-T Cell Therapy Market for PBCAR0191 : Sales Forecast, till 2035 (USD Million)
Figure 22.40 CAR-T Cell Therapy Market for NexCAR19 : Sales Forecast, till 2035 (USD Million)
Figure 23.1 Channels Used for Promotional Campaigns
Figure 23.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 23.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 23.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 23.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 23.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 23.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 23.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 23.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 23.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 23.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 23.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 23.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 23.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 23.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 25.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Clinical Trial Analysis
Figure 25.3 Concluding Remarks: Key Opinion Leaders
Figure 25.4 Concluding Remarks: Partnerships & Collaborations
Figure 25.5 Concluding Remarks: Funding and Investment Analysis
Figure 25.6 Concluding Remarks: Patent Analysis
Figure 25.7 Concluding Remarks: Market Forecast